| Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO. 17 trial N Mittmann, HJ Au, D Tu, CJ O'Callaghan, PK Isogai, CS Karapetis, ... Journal of the National Cancer Institute 101 (17), 1182-1192, 2009 | 142 | 2009 |
| Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer PA Bradbury, D Tu, L Seymour, PK Isogai, L Zhu, R Ng, N Mittmann, ... Journal of the National Cancer Institute 102 (5), 298-306, 2010 | 82 | 2010 |
| Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer RW Jang, PK Isogai, N Mittmann, PA Bradbury, FA Shepherd, R Feld, ... Journal of Thoracic Oncology 5 (12), 1953-1957, 2010 | 59 | 2010 |
| Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients N Lathia, PK Isogai, CD Angelis, TJ Smith, M Cheung, N Mittmann, ... Journal of the National Cancer Institute 105 (15), 1078-1085, 2013 | 41 | 2013 |
| Evaluation of the cost-effectiveness of electrical stimulation therapy for pressure ulcers in spinal cord injury N Mittmann, BC Chan, BC Craven, PK Isogai, P Houghton Archives of physical medicine and rehabilitation 92 (6), 866-872, 2011 | 30 | 2011 |
| Addendum to CADTH’s guidelines for the economic evaluation of health technologies: specific guidance for oncology products N Mittmann, WK Evans, A Rocchi, CJ Longo, HJ Au, D Husereau, ... Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009 | 27 | 2009 |
| Utilization and costs of home care for patients with colorectal cancer: a population-based study N Mittmann, N Liu, J Porter, SJ Seung, PK Isogai, R Saskin, MC Cheung, ... Canadian Medical Association Open Access Journal 2 (1), E11-E17, 2014 | 22 | 2014 |
| Population-based home care services in breast cancer: utilization and costs N Mittmann, PK Isogai, R Saskin, N Liu, JM Porter, MC Cheung, NB Leighl, ... Current Oncology 19 (6), e383, 2012 | 22 | 2012 |
| Nursing workload associated with hospital patient care N Mittmann, SJ Seung, LF Pisterzi, PK Isogai, D Michaels Disease Management & Health Outcomes 16 (1), 53-61, 2008 | 22 | 2008 |
| Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of … N Mittmann, HJ Au, D Tu, CJ O’Callaghan, PK Isogai, CS Karapetis, ... J Natl Cancer Inst 101 (17), 1182-1192, 2009 | 17 | 2009 |
| Guidelines for health technologies: specific guidance for oncology products in Canada N Mittmann, WK Evans, A Rocchi, CJ Longo, HJ Au, D Husereau, ... Value in health 15 (3), 580-585, 2012 | 16 | 2012 |
| Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment N Lathia, PK Isogai, SE Walker, C De Angelis, MC Cheung, JS Hoch, ... Supportive Care in Cancer 21 (1), 245-251, 2013 | 14 | 2013 |
| End-of-life home care utilization and costs in patients with advanced colorectal cancer N Mittmann, N Liu, JM Porter, PK Isogai, R Saskin, MC Cheung, NB Leighl, ... J Community Support Oncol 12 (3), 92-98, 2014 | 11 | 2014 |
| Prediction of health preference values from CD4 counts in individuals with HIV PK Isogai, S Rueda, AR Rachlis, SB Rourke, N Mittmann Medical Decision Making 33 (4), 558-566, 2013 | 7 | 2013 |
| Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group: Prospective cost … N Mittmann, HJ Au, D Tu, CJ O'Callaghan, PK Isogai, CS Karapetis, ... J Natl Cancer Inst 101 (17), 1182-1192, 2009 | 7 | 2009 |
| NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer PA Bradbury, D Tu, L Seymour, PK Isogai, L Zhu, R Ng, N Mittmann, ... J Natl Cancer Inst 102, 298-306, 2010 | 6 | 2010 |
| Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness PA Bradbury, D Tu, L Seymour, R Ng, L Zhu, PK Isogai, N Mittmann, ... Journal of Clinical Oncology 26 (15_suppl), 6531-6531, 2008 | 5 | 2008 |
| Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy. N Lathia, PK Isogai, S Walker, MC Cheung, M Krahn, C DeAngelis, ... Blood, The Journal of the American Society of Hematology 114 (22), 2475-2475, 2009 | 3 | 2009 |
| PCN78 DERIVATION OF UTILITY VALUES FROM EORTC QLQC30 IN LUNG CANCER RW Jang, N Mittmann, P Isogai, PA Bradbury, NB Leighl Value in Health 11 (3), A77-A78, 2008 | 3 | 2008 |
| PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PA Bradbury, R Jang, P Isogai, R Ng, N Mittmann, W Evans, FA Shepherd, ... Value in Health 11 (3), A72, 2008 | 3 | 2008 |
